🇺🇸 FDA
Patent

US 7569586

Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

granted A61PA61P11/00A61P11/06

Quick answer

US patent 7569586 (Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity) held by Theravance, Inc. expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Aug 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61P, A61P11/00, A61P11/06, A61P11/08, A61P11/16